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Neil HallIn the field of genomics we academics have always
worked closely with our industrial partners who develop
the tools of the trade. Recently this relationship has been
dominated by Illumina, a company who, more than any
other, has propelled DNA sequencing from a glamour
branch of genetics to the most exciting area of biomed-
ical science to work in. For the last few years Illumina
has left most of us in besotted awe of their machines;
like wide-eyed Apple groupies we never tire of discuss-
ing the awesomeness of their technology. Illumina have
powered the genomic revolution and we can only hold
up our hands in admiration, as we have been beneficiar-
ies of their success just as much as their shareholders.
You may almost call it symbiotic - but you would be
wrong. Recent events should remind us that we are cus-
tomers not colleagues.
On January 14 Illumina made a major announcement
at the JP Morgan Healthcare conference [1]. They un-
veiled the Hiseq X Ten, an amazing new instrument that
they say:
 Can sequence a human genome for less than $1,000
(so we can all stop predicting when that’s going to
happen now)
 Can only be bought in batches of 10 at an eye
watering $10Million
 Can only be used to sequence human DNA
Yes! it can ONLY be used to sequence human DNA!
Heckles should always be raised whenever a scientist
hears something from a science-led company that
sounds like bad science. Now, last time I checked, and it
has been a while since I read much on basic DNA chem-
istry, human DNA is … well… deoxyribonucleic acid; in
a similar way to mouse DNA, banana DNA, armadillo
DNA and Mycobacterium tuberculosis DNA. Many of
my research hypotheses are based on this naïve assump-
tion, but when I heard about the X Ten, it seemed Illu-
mina had hit upon some unique intrinsic quality of ourCorrespondence: Neil.Hall@liverpool.ac.uk
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allowing their new machine to only work on our highly
specialized genetic code. The intelligent design army
would be delighted, and that’s always a bad sign. But
people who have been hanging around the next-
generation sequencing scene in the last five years or so
were crumpling their noses at this news as everything
about it smelled fishy, not just the special properties of
human DNA bit. Why not announce it at the AGBT
meeting like everyone else? Why 10 at a time? (Can you
imagine the iPad Ten or the Ferrari Ten?) What were
Illumina up to here?
First, let’s look at why this machine only sequences hu-
man DNA - it’s because the conditions of purchase re-
quire that you only use it for human DNA. It is not
optimized for human DNA, Illumina just don’t want you
to use it for anything else. In the same way that a Hew-
lett Packard printer could work with third party print
cartridges, or DVDs bought in Europe could work in the
USA; the reason they don’t is that technical or legal
roadblocks have been built to limit these systems. Not
because it makes them better, it just keeps the customers
under control. And if you think that this restriction will
be like the days when we were only supposed to use Taq
that was ‘licensed to PCR’ but we all used the cheap stuff
from Promega anyway, it won’t be - this rule will be
enforced.
The motivation behind all this is revealed in where the
X Ten was announced; at a healthcare investment con-
ference. It’s clear who the perceived beneficiaries of this
new machine will be. Also of note is Illumina’s hand-
break U-turn in strategy from ‘cheap sequencing for all’
to ‘cheap sequencers for the wealthy centers’ by only
selling the machine in packs of 10. Although instru-
ments were announced that were aimed at smaller labs,
the NextSeq and a cheaper MiSeq, these can’t compete
in cost per base with the X Ten. Blogger Mick Watson,
usually a stalwart, pom-pom spinning Illumina cheer-
leader (sorry Mick, it’s true), has dubbed this ‘de-democ-
ratizing sequencing’ [2]. The reason for this move is not
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to perform homebrew experiments.
All of this is aimed at engineering market separation
between human genome sequence production and
everyone else. This is worrying in part because the bio-
informatics and laboratory developments at these cen-
ters have driven research in all areas of genomic science.
If they are working on a different technology to the rest
of us we all suffer.
So… why would Illumina wish to segregate the genom-
ics community? My theory is as follows.
In the last year or so BGI bought Complete Genomics
[3] and has been competing quite aggressively on price
with Illlumina for large-scale human DNA sequencing.
Currently the business model of Complete Genomics
has been only to focus on human sequencing, as they
don’t sell technology, they sell a service. Illumina need
to bring out new, cheaper technology to ensure their
market dominance in the all-important human sequen-
cing arena but they can see little advantage in making it
cheap for everyone else, as it will just reduce their bot-
tom line. Hence a super-sequencer that is locked to hu-
man seems like a pretty neat idea to the accountants.
I call this the ‘Accountants sacrificing humans for
profit’ theory. Amongst those I have asked, my theory
has been widely accepted. On the acceptance spectrum,
it is pretty close to the theory of evolution and way
ahead of string theory. Also, I may not be the first per-
son to propose this theory [4].
This sort of control is akin to region encoding of DVD
players, it is a technology which serves to allow industry
greater control over the market, but makes the product
less useful. In science, I can’t think of a parallel. I won-
der if the genomics community has found themselves in
a unique situation where they are subject to the whims
of a commercial cartel. Are there companies that make
telescopes that can only be used to study spiral arm gal-
axies and not nebula ones? Or mass spectrometers that
will only work with carbon containing compounds? Yet
it seems that some institutes are quite willing to be com-
plicit in this exercise and have signed up to have their
hands tied in return for cheap sequence. So that as the
thousands of genomes roll off the new X Ten centers,
Illumina sequence will remain as the industry standard
for human genomics, which places them in prime pos-
ition for rare disease testing, patient stratification and so
on, while ensuring the rest of the bioscience community
does not slipstream any benefit from the technology.
I am sure neo-capitalist readers are gasping to tell me
how market economics works, but I DO GET IT. The
reason Illumina have invested so many research dollars
in this technology is to cash in on the clinical market,
that’s how these companies work. But we academics
have been leveraging the perceived potential of personalgenomics, and the tools developed for it, to drive for-
ward research and discovery in all areas of biological sci-
ence. We have imposed the power of next-generation
sequencing on areas of research such as food security,
global climate change and biodiversity, but apparently
this technology was never meant for everyone - it was
only really developed for the clinical market. I imagine
that some may say that us freeloaders were never going
to pay for the ride so we deserved to be thrown off the
train - that’s market economics - live with it.
But how far do we take this argument? Is it OK that
you don’t get to use the best and cheapest technology if
you are sequencing pathogens that cause HIV, tubercu-
losis or malaria, or if you are developing drought toler-
ant crops or cataloging endangered species? If the
technology exists to drive this research forward, is it OK
to prevent people from using it? When did we start leav-
ing these decisions to industry? I am somewhat sur-
prised that there has been so little discussion around the
principle of a company dictating to scientists what sam-
ples are allowed to be run on their products.
One of the things about working in academic science
that gives me that warm fuzzy feeling inside is that we
are a community held together by a passion for discov-
ery. Regardless of if we work on cancer, infection, plant
development or intertidal bivalve diversity, whether we
are tenured professors or PhD students, we have a com-
mon respect for our shared discipline of science. There
is a humility and nobility to our existence that gives us
an inner smugness, like the Type 1 Volkswagen Beetle
owners who wave at each other as they pass on the road.
Maybe the problem I have with Illumina’s strategy is that
it has nothing to do with discovery, science or even hu-
man health. It grates like fingers scraping the chalkboard
of my academic utopia. This policy, which could prevent
researchers from using technology that may help to
solve some of the great challenges affecting humankind,
is motivated by the same thing that caused some
pharmaceutical companies to try to block generic drug
licenses for developing countries. As the greatest market
manipulator of them all, Bill Gates, once said, ‘You know
capitalism is this wonderful thing that motivates people,
it causes wonderful inventions to be done. But in this
area of diseases of the world at large, it’s really let us
down’ [5].
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